Waxman/Hatch Debate Moves Forward: CHPA Aims To Protect OTC Exclusivity
This article was originally published in The Tan Sheet
Executive Summary
Preservation of the three-year exclusivity awarded for clinical studies supporting Rx-to-OTC switches under the existing Waxman/Hatch Act is the Consumer Healthcare Products Association's top priority as patent reform discussions take shape on Capitol Hill.
You may also be interested in...
Capitol Hill Lawmakers Could Revisit Pearson, DSHEA In 2001
Congressional leaders may be looking to the 107th Congress to initiate hearings on FDA's actions in implementing the Pearson v. Shalala decision.
FTC Generic Drug Survey To Gather Information On Late-Listed Patents
A Federal Trade Commission inquiry into generic drug competition will include an examination of late-listed patents.
Drug Expiration Date Rationale Requested By Waxman
Data on FDA's expiration date policies and safety/ effectiveness standards for OTC and Rx drugs are requested by Rep. Henry Waxman (D-Calif.) in a May 19 letter to FDA.